MDRNA to Acquire Cequent in $46M Stock Deal | GenomeWeb

MDRNA has agreed to acquire privately held RNAi drug shop Cequent Pharmaceuticals in an all-stock deal valued at roughly $46 million, the companies said this week as RNAi News went to press.

Through the transaction, MDRNA will gain Cequent's orally delivered transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.